The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/27282 |
Resumo: | Objective: The research focuses on addressing the importance of SAH as a potential risk factor in patients affected by COVID-19. Methods: The methodology adopted in the present study was based on a systematic literature review, in its qualitative sphere, the result of studies based on 10 scientific articles, once listed for the formation of this study. Results: The total number of people with SAH in the present sample is 5,234 with a mean age of 60 years. The most used drugs were Calcium Channel Antagonists, Angiotensin Receptor Beta Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI) and Alpha Blockers. In this meander, the results showed that the use of (ACEI) and Angiotensin Receptor Blockers (ARB), compared to non-ACEI/ARB, do not worsen COVID-19. Current evidence suggests that SARIs should be continued in the case of patients infected with the virus. Some studies have reported that SAH patients are at greater risk of having a more serious condition if they test positive for the new strain of coronavirus. Conclusion: The present research concluded that hypertensive patients with COVID-19 are at greater risk of worsening the disease than non-hypertensive patients. These findings reveal that the worsening of the condition of hypertensive patients and those with COVID-19 is due to the renin-angiotensin-aldosterone system (RAAS), which ends up favoring the binding of the virus to the body of these individuals. |
id |
UNIFEI_d02bc6b6149416fbd32c7b04940a6a43 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/27282 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic reviewLos efectos del COVID-19 en pacientes con hipertensión arterial sistémica: una revisión sistemáticaOs efeitos da COVID-19 em pacientes com hipertensão arterial sistêmica: uma revisão sistemáticaCovid-19Systemic Arterial HypertensionHypertensive.Covid-19Hipertensión Arterial SistémicaHipertensos.Covid-19Hipertensão Arterial SistêmicaHipertensos.Objective: The research focuses on addressing the importance of SAH as a potential risk factor in patients affected by COVID-19. Methods: The methodology adopted in the present study was based on a systematic literature review, in its qualitative sphere, the result of studies based on 10 scientific articles, once listed for the formation of this study. Results: The total number of people with SAH in the present sample is 5,234 with a mean age of 60 years. The most used drugs were Calcium Channel Antagonists, Angiotensin Receptor Beta Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI) and Alpha Blockers. In this meander, the results showed that the use of (ACEI) and Angiotensin Receptor Blockers (ARB), compared to non-ACEI/ARB, do not worsen COVID-19. Current evidence suggests that SARIs should be continued in the case of patients infected with the virus. Some studies have reported that SAH patients are at greater risk of having a more serious condition if they test positive for the new strain of coronavirus. Conclusion: The present research concluded that hypertensive patients with COVID-19 are at greater risk of worsening the disease than non-hypertensive patients. These findings reveal that the worsening of the condition of hypertensive patients and those with COVID-19 is due to the renin-angiotensin-aldosterone system (RAAS), which ends up favoring the binding of the virus to the body of these individuals.Objetivo: La investigación se centra en abordar la importancia de la HAS como potencial factor de riesgo en pacientes afectados por COVID-19. Métodos: La metodología adoptada en el presente estudio se basó en una revisión sistemática de la literatura, en su esfera cualitativa, resultado de estudios basados en 10 artículos científicos, una vez enumerados para la formación de este estudio. Resultados: El total de personas con HAS en la presente muestra es de 5.234 con una edad media de 60 años. Los fármacos más utilizados fueron los Antagonistas de los Canales de Calcio, los Beta Bloqueadores de los Receptores de Angiotensina (ARB), los Inhibidores de la Enzima Convertidora de Angiotensina (IECA) y los Alfa Bloqueadores. En este meandro, los resultados mostraron que el uso de (ACEI) y bloqueadores de los receptores de angiotensina (ARB), en comparación con no-ACEI/ARB, no empeoran el COVID-19. La evidencia actual sugiere que las IRAG deben continuarse en el caso de pacientes infectados con el virus. Algunos estudios han informado que los pacientes con HSA tienen un mayor riesgo de tener una afección más grave si dan positivo para la nueva cepa de coronavirus. Conclusión: La presente investigación concluyó que los pacientes hipertensos con COVID-19 tienen mayor riesgo de empeorar la enfermedad que los pacientes no hipertensos. Estos hallazgos revelan que el empeoramiento del estado de los pacientes hipertensos y con COVID-19 se debe al sistema renina-angiotensina-aldosterona (SRAA), que acaba favoreciendo la unión del virus al organismo de estos individuos.Objetivo: A pesquisa tem como foco abordar a importância da HAS como um potencial fator de risco nos quadros de pacientes acometidos pela COVID-19. Métodos: A metodologia adotada no presente estudo foi baseada em uma revisão bibliográfica sistemática, na sua esfera qualitativa, fruto dos estudos baseados em 10 artigos científicos, uma vez elencados para a formação deste estudo. Resultados: O número total de pessoas com HAS na amostra presente é de 5.234 com faixa etária média de 60 anos. Os fármacos mais utilizados foram Antagonistas dos Canais de Cálcio, Betabloqueadores dos Receptores de Angiotensina (BRA), Inibidores da Enzima Conversora de Angiotensina (IECA) e Alfabloqueadores. Nesse meandro, os resultados demostraram que o uso de (IECA) e os bloqueadores dos receptores de Angiotensina (BRA), comparado aos não IECA/BRA, não agravam a COVID-19. A evidencia atual sugere que os ISRAA devem ser continuados em caso de pacientes contaminados pelo vírus. Alguns estudos relataram que pacientes HAS tem maior risco de apresentar um quadro mais grave em caso de positivo para a nova cepa do coronavírus. Conclusão: A presente pesquisa concluiu que pacientes hipertensos portadores de COVID-19 tem maior risco de agravamento da doença do que os não hipertensos. Tais achados revelam que a piora do quadro de pacientes hipertensos e portadores da COVID-19 se dá pelo sistema renina-angiotensina-aldosterona (SRAA), que acabam favorecendo a ligação do vírus ao organismo desses indivíduos.Research, Society and Development2022-03-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2728210.33448/rsd-v11i4.27282Research, Society and Development; Vol. 11 No. 4; e33711427282Research, Society and Development; Vol. 11 Núm. 4; e33711427282Research, Society and Development; v. 11 n. 4; e337114272822525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/27282/23964Copyright (c) 2022 Jemilly Ferreira de Sousa; Edilson Soares Lima; Mônica Aparecida Miranda Carvalho; Pedro Henrique Coêlho Soares; Raquel Santos Muniz; Renandro de Carvalho Reishttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSousa, Jemilly Ferreira deLima, Edilson SoaresCarvalho, Mônica Aparecida MirandaSoares, Pedro Henrique Coêlho Muniz, Raquel SantosReis, Renandro de Carvalho2022-03-27T17:17:09Zoai:ojs.pkp.sfu.ca:article/27282Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:04.634189Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review Los efectos del COVID-19 en pacientes con hipertensión arterial sistémica: una revisión sistemática Os efeitos da COVID-19 em pacientes com hipertensão arterial sistêmica: uma revisão sistemática |
title |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review |
spellingShingle |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review Sousa, Jemilly Ferreira de Covid-19 Systemic Arterial Hypertension Hypertensive. Covid-19 Hipertensión Arterial Sistémica Hipertensos. Covid-19 Hipertensão Arterial Sistêmica Hipertensos. |
title_short |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review |
title_full |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review |
title_fullStr |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review |
title_full_unstemmed |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review |
title_sort |
The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review |
author |
Sousa, Jemilly Ferreira de |
author_facet |
Sousa, Jemilly Ferreira de Lima, Edilson Soares Carvalho, Mônica Aparecida Miranda Soares, Pedro Henrique Coêlho Muniz, Raquel Santos Reis, Renandro de Carvalho |
author_role |
author |
author2 |
Lima, Edilson Soares Carvalho, Mônica Aparecida Miranda Soares, Pedro Henrique Coêlho Muniz, Raquel Santos Reis, Renandro de Carvalho |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Sousa, Jemilly Ferreira de Lima, Edilson Soares Carvalho, Mônica Aparecida Miranda Soares, Pedro Henrique Coêlho Muniz, Raquel Santos Reis, Renandro de Carvalho |
dc.subject.por.fl_str_mv |
Covid-19 Systemic Arterial Hypertension Hypertensive. Covid-19 Hipertensión Arterial Sistémica Hipertensos. Covid-19 Hipertensão Arterial Sistêmica Hipertensos. |
topic |
Covid-19 Systemic Arterial Hypertension Hypertensive. Covid-19 Hipertensión Arterial Sistémica Hipertensos. Covid-19 Hipertensão Arterial Sistêmica Hipertensos. |
description |
Objective: The research focuses on addressing the importance of SAH as a potential risk factor in patients affected by COVID-19. Methods: The methodology adopted in the present study was based on a systematic literature review, in its qualitative sphere, the result of studies based on 10 scientific articles, once listed for the formation of this study. Results: The total number of people with SAH in the present sample is 5,234 with a mean age of 60 years. The most used drugs were Calcium Channel Antagonists, Angiotensin Receptor Beta Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI) and Alpha Blockers. In this meander, the results showed that the use of (ACEI) and Angiotensin Receptor Blockers (ARB), compared to non-ACEI/ARB, do not worsen COVID-19. Current evidence suggests that SARIs should be continued in the case of patients infected with the virus. Some studies have reported that SAH patients are at greater risk of having a more serious condition if they test positive for the new strain of coronavirus. Conclusion: The present research concluded that hypertensive patients with COVID-19 are at greater risk of worsening the disease than non-hypertensive patients. These findings reveal that the worsening of the condition of hypertensive patients and those with COVID-19 is due to the renin-angiotensin-aldosterone system (RAAS), which ends up favoring the binding of the virus to the body of these individuals. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-03-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/27282 10.33448/rsd-v11i4.27282 |
url |
https://rsdjournal.org/index.php/rsd/article/view/27282 |
identifier_str_mv |
10.33448/rsd-v11i4.27282 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/27282/23964 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 4; e33711427282 Research, Society and Development; Vol. 11 Núm. 4; e33711427282 Research, Society and Development; v. 11 n. 4; e33711427282 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052707461136384 |